Get the Daily Brief
Latest Biotech News
Apogee’s long‑acting eczema drug: 3‑ and 6‑month dosing sustains response
Apogee Therapeutics released mid‑stage maintenance data showing its anti‑IL‑13 antibody, zumilokibart (APG‑777), produced durable clinical responses with three‑ and six‑month maintenance dosing in...
Kali inks $1.2B Sanofi pact — trispecific T‑cell engager licensed
Kali Therapeutics licensed its lead trispecific T‑cell engager KT‑501 to Sanofi in a deal worth up to $1.2 billion, including substantial near‑term payments. Sanofi described the arrangement as a...
Crossbow raises $77M — funds CBX‑250 first‑in‑human push
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and lead candidate CBX‑250, a T‑cell engager targeting intracellular tumor antigens via HLA‑presented peptides....
Rivia raises $15M — agentic AI to cut trial review times
Swiss startup Rivia closed a $15 million Series A to scale an agentic AI platform intended to unify and structure clinical trial data in real time and surface prioritized data‑quality issues. CEO...
China’s trial reforms: implied approval accelerates IND starts
Analysts and US policymakers highlighted sweeping changes in China’s clinical‑trial rules that have dramatically shortened timelines for starting human studies, including a 2018 'implied approval'...
Insmed’s Arikayce wins late‑stage trial — eyes front‑line lung use
Insmed reported positive Phase 3 data showing Arikayce added to standard therapy improved respiratory symptoms and culture conversion rates in patients with newly diagnosed Mycobacterium avium...
Laigo extends seed to €17M — protein‑degradation tech moves toward clinic
Laigo Bio extended its seed round to €17 million as it advances a novel E3 ligase‑based targeted protein degradation platform toward clinical translation. The additional capital will support...
Tessera wins Gates grant — genetic strategies for scalable HIV cure
Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage research exploring genetic approaches aimed at a scalable HIV cure. Tessera said funding will...
Lyme vaccine shows strong efficacy: Pfizer, Valneva vow regulatory push
Pfizer and Valneva said their Phase 3 Lyme disease vaccine reduced cases by roughly 70–73% but missed the trial’s pre-specified statistical threshold. The companies acknowledged...
Insmed eyes front-line expansion after Arikayce late‑stage win
Insmed reported a Phase 3 victory for Arikayce in treatment‑naïve patients with Mycobacterium avium complex (MAC) lung infection, meeting the trial’s primary goals and showing improved respiratory...
Apogee’s long‑acting eczema drug promises less frequent dosing — rivals in sight
Apogee Therapeutics reported mid‑stage maintenance data showing its anti‑IL‑13 candidate induced durable skin and itch relief with far less frequent injections than current biologics. In the Phase...
Novartis buys Pikavation for up to $3B — bolsters PI3Kα cancer push
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. Novartis said SNV4818 aims to selectively...
Sanofi inks $1.2B deal for Kali trispecific — $180M upfront signals renewed T‑cell bet
Sanofi struck a partnership to license a Phase 1‑stage trispecific T‑cell engager from Kali Therapeutics, paying $180 million upfront and structuring the broader pact at up to $1.2 billion. The...
Crossbow closes $77M Series B to advance T‑cell engager for myeloid malignancies
Crossbow Therapeutics raised $77 million in a Series B round to advance its T‑Bolt platform and lead candidate CBX‑250, a T‑cell engager targeting relapsed or refractory myeloid malignancies. CEO...
Gates Foundation funds Tessera to pursue scalable genetic approaches toward HIV cure
Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage work on genetic strategies aimed at a scalable cure for HIV. Tessera will use the funding to...
BIO board member warns Congress: China’s trial speed gives biotech advantage
Dr. Jacob Becraft, a BIO Board member and CEO of Strand Therapeutics, told the House Select Committee on China that China’s accelerated pathway to first‑in‑human trials is creating a competitive...
Varseta‑M data jolt CytomX shares: 32% ORR ignites volatile trading
CytomX released dose‑expansion data showing varsetatug masetecan (varseta‑M), an EpCAM‑targeting masked ADC, produced a 32% overall response rate and median progression‑free survival of 7.1 months...
WuXi AppTec shifts revenue mix toward US amid military‑link scrutiny
WuXi AppTec’s recent disclosure highlighted increasing revenue dependence on U.S. business as the contract research and manufacturing organization navigates investor concern about alleged ties to...
Aurinia boardroom coup — Kevin Tang ousts CEO and C-suite
Kevin Tang, an activist biotech investor, has consolidated control of Aurinia Pharmaceuticals and replaced the CEO and senior management, according to a securities filing. The filing shows Tang...
Zegfrovy beats chemo: Dizal posts Phase 3 first-line lung cancer win
Dizal reported Phase 3 data showing its drug Zegfrovy improved progression‑free survival versus chemotherapy in first‑line non‑small cell lung cancer (NSCLC) patients. The readout positions...